secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2026-08-10T11:19:57+00:00
Accession:  0001193125-26-341239
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie to acquire Apogee for $135.11/share (~$10.9B); Q2 results reported
-------------------------------------------------------------------------

- AbbVie to acquire Apogee for $135.11/share cash, ~$10.9B equity value; expected close Q3 2026.
- Phase 2 APEX Part B met endpoints: 65.9% EASI-75 (41.9% placebo-adjusted) with mid-dose zumilokibart.
- Cash $1.3B at June 30, 2026; Q2 net loss $85.9M vs $66.1M year ago.
- Blackstone financing collaboration up to $1.3B non-dilutive for zumilokibart development.
- Phase 3 initiation for zumilokibart in atopic dermatitis planned this year; EoE and asthma trials set.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000119312526341239/0001193125-26-341239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000119312526341239/apge-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-341239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer